China-ready by design: Leveraging NMPA’s new 30‑working day IND pathway

China's NMPA Accelerates IND Pathway for Innovative Oncology Drugs

The press release highlights China's growing prominence as a global hub for oncology clinical trials, driven by its vast and diverse patient population, which leads to significantly faster recruitment timelines. The National Medical Products Administration (NMPA) has introduced an expedited 30-working day IND 'no-objection' pathway for innovative products, a substantial reduction from the standard 60 days. This regulatory evolution, coupled with lower operational costs, makes China an increasingly attractive destination for global drug development, provided sponsors are adequately prepared and partner with experienced contract research organizations (CROs) like Caidya.

• China has emerged as a key destination for oncology clinical trials, with its sites increasingly integrated into multinational studies. This is primarily due to its large and diverse patient population, which enables notably faster recruitment timelines, and a sophisticated oncology clinical trial network, demonstrating leadership in early-phase cancer trials and growing contributions to international multicenter studies.
• The National Medical Products Administration (NMPA) now offers a 30-working day IND 'no-objection' pathway, following a successful pilot in 2024. This expedited route, broadly analogous to the FDA’s review period, is intended for innovative products with new active substances, especially those with globally synchronized clinical development programs or NMPA designations like the Pediatric SPARK Plan or Priority Innovative Drugs.
• To effectively utilize the NMPA's 30-working day pathway, sponsors must be 'China-ready.' This involves confirming asset eligibility as a Class I innovative drug, strategically deciding if the expedited timeline suits global strategy, selecting experienced oncology centers and principal investigators, implementing robust risk management, committing to rapid study start-up, and preparing a comprehensive IND dossier to NMPA and CDE standards.

Why China's Patient Pool is Critical for Addressing Oncology Unmet Needs

The global oncology landscape continues to be defined by significant unmet needs, with substantial disparities in disease burden and treatment access persisting across diverse populations. Addressing these complex challenges requires robust clinical evidence generation, highlighting the critical value of large, heterogeneous patient cohorts for advancing research and development. Key areas of focus over the past three years include specific underserved populations, persistent socioeconomic inequities, and systemic challenges in clinical research.

• Geographic and Socioeconomic Disparities: Significant inequities in cancer outcomes are linked to geography and socioeconomic status. For instance, in the US Delta region, Black men exhibit the highest cancer mortality rate (ASR = 346.9 per 100,000). Access to advanced therapies like stereotactic radiosurgery (SRS) is less likely for patients with lower income (aOR = 0.88), lower educational attainment (aOR = 0.88), or public insurance (aOR = 0.86). These disparities persist for patients treated outside of academic centers, underscoring the need for targeted interventions to ensure equitable access.

• Underserved Patient Populations: Rare and pediatric cancers represent populations with distinct and pressing needs. Patients with rare cancers, which account for 25% of all cancer diagnoses, face challenges including misdiagnosis and difficulty accessing specialized care. Similarly, childhood cancers present a major global burden, causing 70.45 million DALYs in 2021. Low-Socio-Demographic Index (SDI) countries face escalating burdens due to delayed diagnoses and fragmented care, with a widening socioeconomic inequality gap reflected in the DALYs concentration index.

• Clinical Trial Enrollment and Design: Insufficient patient accrual remains the leading cause of cancer trial terminations, particularly for rare diseases. Median monthly enrollment for FDA-approved drugs was substantially lower for ultra-rare orphan indications (8 patients) compared to non-orphan indications (38 patients). This slow enrollment impedes progress, despite evidence that trials focused exclusively on rare cancers can achieve higher success rates (42.2%) than those for common cancers (38.2%).

• Shifting Global Cancer Burden and Therapeutic Gaps: The global distribution of cancer is evolving, with widening disparities. For tracheal, bronchus, and lung (TBL) cancers, mortality is projected to decline in high-SDI regions but persist or increase in low-SDI countries. Furthermore, fundamental research gaps remain, particularly in metastatic disease, where no universal mutational landscape has been identified as predictive of metastasis. Addressing tumor heterogeneity and evolving resistance mechanisms requires new strategies, such as adaptive, biomarker-guided approaches and novel platforms like personalized tumor organoids (PTOs).

Addressing Oncology Treatment Gaps with NMPA's Faster IND Pathway

Oncology treatment continues to be constrained by persistent biological and systemic barriers that limit durable patient benefit, even as targeted and immuno-oncology approaches have advanced the field. These challenges span drug resistance mechanisms, therapeutic index limitations, cost barriers, and unresolved knowledge gaps—underscoring the need for faster development pathways, such as NMPA's accelerated IND process, to bring next-generation solutions to patients more efficiently.

• Drug resistance remains the most pervasive obstacle, frequently cited as the leading cause of treatment failure and chemotherapy discontinuation; resistance arises through four distinct mechanisms in targeted therapy—target mutations, reactivation of the targeted pathway, hyperactivation of alternative pathways, and cross-talk with the tumor microenvironment—compounded by intra-tumor heterogeneity and the role of resilient cancer stem cells (CSCs) in driving relapse.

• Conventional therapies suffer from a narrow therapeutic index and low specificity, with radiation, surgery, chemotherapy, molecular targeted therapy, immunotherapy, and antibody-drug conjugates (ADCs) all associated with serious side effects; this narrow margin between cancer cell toxicity and normal cell preservation continues to limit outcomes despite progress in synthetic anti-cancer drug development.

• Hypoxia within advanced solid tumors represents a distinct resistance mechanism, contributing—alongside broader resistance to conventional anti-tumor therapies—to treatment failure in patients with advanced disease.

• Cost and accessibility remain significant barriers, as advanced target-specific modalities such as immunotherapy and stem cell therapy are often prohibitively expensive, rendering them unaffordable for many patients, particularly in lower-resource settings.

• Disease-specific limitations persist, exemplified by prostate cancer, where a paucity of innovative molecular targeted therapies and ineligibility for immunological strategies confines clinical intervention largely to surgery or radiotherapy for organ-confined disease and systemic hormone therapy for metastatic disease—with relapse remaining nearly inevitable and palliative care the eventual endpoint.

• Critical knowledge gaps continue to hinder progress, including incomplete understanding of the molecular mechanisms driving resistance to specific therapies, unresolved questions around the mechanisms underlying combination therapies, and poorly characterized regulatory pathways of ion channels in cancer stem cells—highlighting that despite substantial advances in immuno-oncology, key unresolved problems remain.

Designing 'China-Ready' Oncology Trials: Key Parameters and Endpoints

Designing successful oncology clinical trials requires careful consideration of key parameters and endpoints to demonstrate clinical benefit and secure regulatory approval. While Overall Survival (OS) remains the gold standard, a variety of other endpoints, including Progression-Free Survival (PFS) and Objective Response Rate (ORR), are commonly employed across different trial phases. The following table summarizes critical design elements and outcomes observed in pivotal oncology studies from recent literature.